Eikon Therapeutics initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Sean Laaman initiated coverage of Eikon Therapeutics (EIKN) with an Overweight rating and $32 price target Eikon is a late-stage clinical company with a focus on oncology, the analyst tells investors in a research note. The firm says the company’s data to date are supportive of “early de-risking” of the company’s clinical-stage assets. It says Eikon’s multiple data readouts across the pipeline in the second half of 2026 “create clear opportunities for upside.”